SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Hilbrich L.)
 

Sökning: WFRF:(Hilbrich L.) > Telmisartan to prev...

  • Yusuf, S.Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, ON, Canada; Population Health Research Institute, McMaster University, Hamilton, ON, Canada; Population Health Research Institute, McMaster University, Hamilton, ON, Canada; dHamilton Health Sciences, Hamilton, ON, Canada (författare)

Telmisartan to prevent recurrent stroke and cardiovascular events

  • Artikel/kapitelEngelska2008

Förlag, utgivningsår, omfång ...

  • Massachusetts medical society,2008

Nummerbeteckningar

  • LIBRIS-ID:oai:gup.ub.gu.se/86347
  • https://gup.ub.gu.se/publication/86347URI
  • https://doi.org/10.1056/NEJMoa0804593DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-81161URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:117567179URI

Kompletterande språkuppgifter

  • Språk:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • BACKGROUND: Prolonged lowering of blood pressure after a stroke reduces the risk of recurrent stroke. In addition, inhibition of the renin-angiotensin system in high-risk patients reduces the rate of subsequent cardiovascular events, including stroke. However, the effect of lowering of blood pressure with a renin-angiotensin system inhibitor soon after a stroke has not been clearly established. We evaluated the effects of therapy with an angiotensin-receptor blocker, telmisartan, initiated early after a stroke. METHODS: In a multicenter trial involving 20,332 patients who recently had an ischemic stroke, we randomly assigned 10,146 to receive telmisartan (80 mg daily) and 10,186 to receive placebo. The primary outcome was recurrent stroke. Secondary outcomes were major cardiovascular events (death from cardiovascular causes, recurrent stroke, myocardial infarction, or new or worsening heart failure) and new-onset diabetes. RESULTS: The median interval from stroke to randomization was 15 days. During a mean follow-up of 2.5 years, the mean blood pressure was 3.8/2.0 mm Hg lower in the telmisartan group than in the placebo group. A total of 880 patients (8.7%) in the telmisartan group and 934 patients (9.2%) in the placebo group had a subsequent stroke (hazard ratio in the telmisartan group, 0.95; 95% confidence interval [CI], 0.86 to 1.04; P=0.23). Major cardiovascular events occurred in 1367 patients (13.5%) in the telmisartan group and 1463 patients (14.4%) in the placebo group (hazard ratio, 0.94; 95% CI, 0.87 to 1.01; P=0.11). New-onset diabetes occurred in 1.7% of the telmisartan group and 2.1% of the placebo group (hazard ratio, 0.82; 95% CI, 0.65 to 1.04; P=0.10). CONCLUSIONS: Therapy with telmisartan initiated soon after an ischemic stroke and continued for 2.5 years did not significantly lower the rate of recurrent stroke, major cardiovascular events, or diabetes. (ClinicalTrials.gov number, NCT00153062.)

Ämnesord och genrebeteckningar

  • MEDICIN OCH HÄLSOVETENSKAP Medicinska och farmaceutiska grundvetenskaper Neurovetenskaper hsv//swe
  • MEDICAL AND HEALTH SCIENCES Basic Medicine Neurosciences hsv//eng
  • Aged
  • Angiotensin-Converting Enzyme Inhibitors/adverse effects/*therapeutic use
  • Benzimidazoles/adverse effects/*therapeutic use
  • Benzoates/adverse effects/*therapeutic use
  • Blood Pressure/drug effects
  • Cardiovascular Diseases/epidemiology/mortality/*prevention & control
  • Creatinine/blood
  • Diabetes Mellitus/epidemiology
  • Female
  • Follow-Up Studies
  • Heart Failure/epidemiology/prevention & control
  • Humans
  • Kaplan-Meiers Estimate
  • Male
  • Middle Aged
  • Myocardial Infarction/epidemiology/prevention & control
  • Potassium/blood
  • Recurrence/prevention & control
  • Stroke/*drug therapy/prevention & control
  • Treatment Failure

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Diener, H. C.University of Duisberg-Essen, Essen, Germany (författare)
  • Sacco, R. L.Miller School of Medicine, University of Miami, Miami, United States,Clinical Trials Methodology Group, McMaster University, Hamilton, ON, Canada (författare)
  • Cotton, D.Boehringer Ingelheim, Ridgefield, CT, United States (författare)
  • Ounpuu, S. (författare)
  • Lawton, W. A. (författare)
  • Palesch, Y.Medical University, Soudi Carolina, Charleston, United States (författare)
  • Martin, R. H.Medical University, Soudi Carolina, Charleston, United States (författare)
  • Albers, G. W.Stanford University, Medical Center, Palo Alto, CA, United States (författare)
  • Bath, P.University of Nottingham, Nottingham, United Kingdom (författare)
  • Bornstein, N.Ichilov Medical Center, Tel-Aviv, Israel (författare)
  • Chan, B. P.National University Hospital, Singapore, Singapore,St. Johns's Medical College, Bangalore, India (författare)
  • Chen, S. T.Chang Gung Memorial Hospital, Tapei, Taiwan (författare)
  • Cunha, L.Hospitais da Universidade de Coimbra, Coimbra, Portugal (författare)
  • Dahlöf, Björn,1953Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin,Institute of Medicine, Department of Emergeny and Cardiovascular Medicine,Sahlgrenska University Hospital, Östra, Göteborg, Sweden(Swepub:gu)xdahbj (författare)
  • De Keyser, J.University Medical Center Groningen, Groningen, Netherlands (författare)
  • Donnan, G. A.National Stroke Research Institute, Austin Health, University of Melbourne, Heidelberg West, Australia (författare)
  • Estol, C.Neurological Center for Treatment and Research, Buenos Aires, Argentina (författare)
  • Gorelick, P.University of Illinois, Chicago, United States (författare)
  • Gu, V. (författare)
  • Hermansson, K. (författare)
  • Hilbrich, L.Boehringer Ingelheim, Ridgefield, CT, United States (författare)
  • Kaste, M.Helsinki University, Central Hospital, Helsinki, Finland (författare)
  • Lu, C.Huashan Hospital, Shanghai, China (författare)
  • Machnig, T. (författare)
  • Pais, P. (författare)
  • Roberts, R. (författare)
  • Skvortsova, V.Russian State Medical University, Moscow, Russian Federation (författare)
  • Teal, P.University of British Columbia, Vancouver, Canada (författare)
  • Toni, D.University La Sapienza, Rome, Italy (författare)
  • VanderMaelen, C.Boehringer Ingelheim, Ridgefield, CT, United States (författare)
  • Voigt, T.Boehringer Ingelheim, Ridgefield, CT, United States (författare)
  • Weber, M.Boehringer Ingelheim, Ridgefield, CT, United States (författare)
  • Yoon, B. W.Seoul National University Hospital, Seoul, South Korea (författare)
  • von Euler, Mia,1967-(författare)
  • Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, ON, Canada; Population Health Research Institute, McMaster University, Hamilton, ON, Canada; Population Health Research Institute, McMaster University, Hamilton, ON, Canada; dHamilton Health Sciences, Hamilton, ON, CanadaUniversity of Duisberg-Essen, Essen, Germany (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:New England Journal of Medicine: Massachusetts medical society359:12, s. 1225-371533-44060028-4793

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy